QQCWB

GV

Biontech Pays Autolus $250M To Use Manufacturing, Car-T Tech

Di: Ava

BioNTech SE SE and Autolus Therapeutics Therapeutics announced a strategic collaboration aimed at advancing both companies‘ autologous CAR-T programs towards commercialization,

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy

Carina Biotech's proprietary CAR-T manufacturing process - Carina Biotech

BioNTech pays Autolus $250M to use Autolus’ manufacturing and clinical site network across the U.K. to help efficiently develop BNT211 for pivotal trials in CLDN6+ tumors. BioNTech pays Autolus $250M to use Autolus’ manufacturing and clinical site network across the U.K. to help efficiently develop BNT211 for pivotal trials in CLDN6+ tumors. BioNTech has brought British company Autolus Therapeutics on board in an intriguing $250 million upfront collaboration. The deal means BioNTech can use Autolus’ manufacturing and

BioNTech is not only handing over $50 million cash but will also buy $200 million of Autolus\u2019 American depositary shares (ADSs) in a private placement.

On an earnings call, Autolus CEO Christian Itin teased a planned update on AUTO1/22 and other candidates in the biotech’s pipeline. BioNTech pays Autolus $250M for BioNTech has entered into a strategic partnership with Autolus Therapeutics to progress the development of CAR-T cell therapy programmes.

Autolus manufactures its product candidates at the Cell and Gene Therapy Catapult manufacturing facility in the UK and has a new manufacturing

BioNTech and Autolus are teaming up to advance both of their CAR-T programs. 1 The strategic alliance will include a $200 million In 2024 Autolus signed a strategic CAR T cell therapy collaboration with BioNTech aimed at advancing both companies’ autologous CAR T programs towards commercialization, pending

BioNTech SE invests £250M in Autolus Therapeutics

A strategic multi-platform R&D collaboration with BioNTech CAR T Cell Therapies BioNTech to financially support obe-cel planned/potential commercial launch in adult ALL (Acute Autolus Therapeutics is building a facility, The Nucleus, in Stevenage, UK, for the manufacture of CAR) T-cell therapies for cancer. Read the latest digital content and updated pharmaceutical media info of Autolus Therapeutics aggregated at PharmaCompass.com.

  • BioNTech and Autolus join forces for CAR-T
  • BioNTech突砍CAR-T！关停美国工厂并裁员
  • Developing Next Generation Programmed T Cell Therapies

BioNTech has announced that it has entered into a strategic collaboration worth over $250m with Autolus Therapeutics to advance both companies’ autologous CAR-T cell BioNTech pays Autolus $250M for manufacturing, CAR-T expertise in wide-ranging collab fiercebiotech.com 21 Rohan Gidvani Strategic Advisor, Biotech & Pharma 2mo Edited

CAR-T Cell Manufacturing - 7TALOS

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards U.K. trial for mRNA-based cancer therapy beginslabpulse.com 4 Connor Hickey 1d BioNTech pays Autolus $250M to use manufacturing, CAR-T tech

德国生物科技巨头BioNTech近日宣布重大业务调整：由于其CLDN6靶向CAR-T疗法BNT211在睾丸癌早期临床试验中表现未达预期，公司将逐步关停位于美国马里 BioNTech pays Autolus $250M for manufacturing, CAR-T expertise in wide-ranging collab

吃尽新冠疫苗红利之后的BioNTech，近日宣布了一项重大业务调整决定：由于其CLDN6靶向CAR-T疗法BNT211在睾丸癌早期临床试验中的表现未达预期，公司计划逐步关停

On an earnings call, Autolus CEO Christian Itin teased a planned update on AUTO1/22 and other candidates in the biotech’s pipeline. BioNTech pays Autolus $250M for Autolus Therapeutics Inc. has picked up plenty of financial momentum, about $600 million worth, in its runup to a November 2024 PDUFA date for its CD19 CAR T therapy.

Developing Next Generation Programmed T Cell Therapies

Earlier this year, BioNTech made another adjustment to its CAR-T pipeline when it chose not to pursue a co-development option with Autolus Therapeutics. The candidate in In a groundbreaking collaboration, BioNTech SE pursuit of innovative cancer treatments has gained a significant boost with a $250 million investment in UK's Autolus Therapeutics . ??

  • BioNTech Inks $250M Deal with Autolus to Advance CAR-T Assets
  • BioNTech放弃一款CAR-T疗法
  • BioNTech inks CAR-T partnership with Autolus
  • Veru needs additional cash for fresh trial of respiratory distress drug
  • BioNTech and Autolus Announce Strategic CAR-T Cell Therapy

BioNTech, a next-generation immunotherapy company, and Autolus Therapeutics, a clinical-stage biopharmaceutical company, announced a strategic collaboration on February Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards

BioNTech is enlisting CAR-T biotech Autolus Therapeutics on a partnership aimed at pushing both of their CAR-T programs toward commercialization, with an eye on its new BioNTech pays Autolus $250M to use Autolus’ manufacturing and clinical site network across the U.K. to help efficiently develop BNT211 for pivotal trials in CLDN6+ tumors. Strategic developments: Strategic alliance with BioNTech SE In February 2024, BioNTech and Autolus announced a strategic CAR T cell therapy collaboration to advance

Autolus granted BioNTech an exclusive license to develop and commercialize therapeutics incorporating certain of Autolus’ proprietary binders along with options to license Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards The collaboration between BioNTech SE and Autolus Therapeutics utilises manufacturing and commercial infrastructure,

BioNTech has passed on Autolus Therapeutic | BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co

BioNTech pays Autolus $250M to use Autolus‘ manufacturing and clinical site network across the U.K. to help efficiently develop BNT211 for pivotal trials in CLDN6+ tumors. Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has

Biontech and Autolus collaborate to advance their CAR T programs

12 个月的总生存率和无事件生存率与 ELIANA 研究相当。 然而，2025 年，BioNTech 决定放弃其与 Autolus 合作开发 AUTO1/22 的选择权，该选择权于 2025 年 2 月到